ArticleEndocrine connections2025
Peripheral blood HIF-1α levels: a study on their predictive ability for early-stage diabetic retinopathy.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the correlation between the levels of hypoxia-inducible factor-1α (HIF-1α) in the peripheral blood of patients with type 2 diabetes (T2D) and early-stage diabetic retinopathy (DR) and to evaluate its potential as a predictor of early DR. Methods: From November 2021 to December 2023, 70 patients who underwent fundus photography at Zhangzhou Second Hospital were recruited. Based on the results, patients were categorized into a T2D group comprising 25 patients and a DR group comprising 45 patients. In addition, 18 healthy individuals who underwent routine physical examinations during the same period were included as a control group. Serum levels of the HIF-1α protein were measured in all three groups. Results: The results indicated that patients in the early-stage DR group had significantly higher levels of HIF-1α, albumin (Alb), Ca and blood urea nitrogen (BUN) compared to the T2D group (P < 0.05). In addition, patients in the DR group exhibited higher levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), fasting plasma glucose (FPG) and glycated hemoglobin (HbA1C) than the control group (P < 0.05). The incidence rates of DR in groups A, B, C and D were 18.18, 31.82, 59.09 and 95.45%, respectively, with statistically significant differences (P < 0.05). Spearman's correlation analysis revealed significant positive correlations between HIF-1α and age, disease duration (years), systolic blood pressure, Cr, FPG and HbA1c, with a strong positive correlation between HIF-1α and HbA1c (P < 0.05) optimal cutoff value of 2.3855 ng/mL. Conclusion: Increased levels of HIF-1α in peripheral blood are closely linked to the development of DR, suggesting that HIF-1α may act as a potential biomarker for the early detection and prediction of DR risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.